Share Prices & Company Research

Market News

11 Mar 2021 | 08:17

Glaxo, Vir advised to stop Covid trial early as drug shows 85% efficacy

(Sharecast News) - Drug companies GlaxoSmithKline and Vir Biotechnology have been advised to finish a final trial of their Covid-19 drug early due to its "profound efficacy". The duo said they would now seek authorisation in the US and other countries after phase-three clinical trials for the VIR-7831 treatment showed the drug reduced hospitalisation and risk of death by 85% and was effective against other variants.

As a result, an independent data monitoring committee, recommended an early end to the trials.

An additional study also indicated the treatment maintained activity against "current circulating variants of concern" including the UK, South Africa and Brazilian strains.

Vir chief executive George Scangos said the results "bring us one step closer to delivering an effective new solution to patients around the globe".

"The dual-action design of VIR-7831 to both block viral entry into healthy cells and clear infected cells, as well as its high barrier to resistance, are key distinguishing characteristics."

"These findings, paired with our pending publication of resistance data, demonstrate the potential of VIR-7831 to prevent the most severe consequences of Covid-19 and highlight its potential ability to protect against the current circulating strains of the virus."

Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.